drugset / Trial / NCT03674463
LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
Phase 1
Unknown
10 enrolled
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of LCAR-B4822M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).
Timeline
- Start
- 2018-07-26
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-B4822M | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | LCAR-B4822M | Cell therapy | 2e+06 cells/kg | Intravenous |